C
CeQur
Developing and commercializing simple drug delivery devices that can be easily integrated into daily life
About CeQur
CeQur Simplicity is a medical device company specializing in innovative insulin delivery systems designed to improve diabetes management. The company serves individuals with diabetes who require mealtime insulin, offering a discreet, compact, and water-resistant patch that simplifies insulin administration. Operating in the healthcare and medical device market, CeQur Simplicity's business model revolves around the sale of its proprietary insulin delivery patches. Revenue is generated through direct sales to consumers and partnerships with healthcare providers. The product is clinically proven to reduce A1C levels and increase Time in Range (TIR), thereby minimizing long-term health complications associated with diabetes. The patch stays in place for up to three days, allowing users to maintain their insulin regimen with less interference and added convenience. CeQur Simplicity aims to ease the burden of multiple daily injections, replacing them with a single patch that delivers rapid-acting insulin with just one click. The company focuses on providing a user-friendly solution that enhances adherence to insulin therapy, ultimately improving patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- Horw, Switzerland
- Employees
- 150
- Open positions
- None listed
- Dealroom signal
- 90.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Diabetes, Remote Monitoring, Metabolism, Wearable, Tech for Patients, Digital Care
- Technology
- Hardware, Deep Tech, Connected Device
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Jun 2026 | $100M | $600M | Undisclosed | ↗ |
| LATE VCOther financing | Jan 2025 | $120M | $480M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for CeQur is 25K monthly website visits, down 35.9% over the last three months. CeQur's team grew 13.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
VI Partners
Schroders
Endeavour Vision
Series B and later9 investors entered at this stage
Danfoss
Woodford Investment Management
Arthurian Life Sciences
Credit Suisse Entrepreneur Capital
Tandem Diabetes Care
Federated Hermes
Ypsomed
GMS Capital- KCKingdon Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CeQur on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CeQur’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.